Horrific health details have been revealed regarding Jamie Foxx’s mysterious medical state.
The Django Unchained star is said to be "partially paralyzed and blind," in addition to a series of other complications after receiving the COVID-19 vaccine, Hollywood journalist A.J. Benza claimed after speaking to a source close to Foxx.
A new study - released this month in the journal Nature - reported a high chance of long-term vision loss among those who received the experimental and largely ineffective mRNA COVID-19 vaccine that was briefly popular in 2021-2022: https://www.conquerclub.com/forum/viewt ... 8&t=239532
Pack Rat wrote:if it quacks like a duck and walk like a duck, it's still fascism
My semen volume once declined significantly following a round of antibiotics for chlamydia, but recovered again within a few weeks. Hopefully Jamie will recover from his drug-induced ailments with similar speed.
Palestinians murdered by Israel during its ongoing illegal invasion of Gaza: 52,535*
WILLIAMS5232 wrote:
as far as dukasaur goes, i had no idea you were so goofy. i mean, you hate your parents so much you'd wish they'd been shot? just move out bro.
Wanted to see what idiotic misinformation is being pushed now by people who get their news from propaganda sites and serial liars.
The CDC states that COVID-19 vaccines are safe, effective, and reduce your risk of severe illness. Hundreds of millions of people have received a COVID-19 vaccine, and serious adverse reactions are uncommon. You should always consult a reputable physician before making any decisions about your health.
Meanwhile, science states it's not effective (here's three of 19 different studies less than six months old I can cite):
March 2023: New Bivalent Vax Between 0% to 29% Effective (preprint study by Cleveland Clinic researchers)
A preprint study by Cleveland Clinic researchers finds the emergency-authorized bivalent vax is 29% effective against the BA.4/5 variant, 20% effective against the BQ variant, and 0% effective against the XB variant. (To receive initial approval in non-emergency conditions, vaccines must demonstrate 50%+ efficacy.)
Among 51017 working-aged Cleveland Clinic employees, the bivalent COVID-19 vaccine was 29% effective in preventing infection while the BA.4/5 lineages were dominant, and 20% effective while the BQ lineages were. Effectiveness was not demonstrated when the XBB lineages were dominant.
----- May 2023: mRNA Vaccines Useless After a Couple Months (Journal of the American Medical Association)
A new study by Italian researchers, published in JAMA, shows that - unless you're willing to get boostered every couple of months (and accept the compounding risks of myocarditis that increase with each new shot) - there's basically no point in getting vaccinated.
This systematic review and meta-analysis of secondary data from 40 studies found that the estimated vaccine effectiveness against both laboratory-confirmed Omicron infection and symptomatic disease was lower than 20% at 6 months from the administration of the primary vaccination cycle and less than 30% at 9 months from the administration of a booster dose.
May 2023: mRNA Vaccines No Better than Placebo (Cell)
A new study by researchers at the Danish Institute of Advanced Science published in the Q1 journal Cell finds there was no statistically significant difference in COVID-19 survival rates between people who received an mRNA vaccine and those who did not. It did find a small, but still statistically significant, difference in survival rates for viral vector vaccines such as AstraZeneca and J&J.
The differences in the effects of adenovirus-vector and mRNA vaccines on overall mortality, if true, would have a major impact on global health. If validated in additional studies, the protective non-specific effects of adenovirus-based vaccines on non-COVID-19 mortality, in addition to their effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may represent an important advantage in vulnerable populations in which cardiovascular mortality is high.
